Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Naive or Receiving Bruton s-Tyrosine Kinase Inhibitor (BTK-I) Therapy

  • STATUS
    Recruiting
Updated on 9 April 2019
cancer
chronic lymphocytic leukemia
lymphoma
ibrutinib
acalabrutinib

Summary

Background:

  • People who have cancer tend to get sick more often. This is in part because of the cancer treatments they get. Because of this, they may get shingles. Scientists had thought people with chronic lymphocytic leukemia (CLL) should not get the shingles vaccine. Now there is a new shingles vaccine that is not live and cannot cause shingles. The new shingles vaccine may protect people with weak immune systems from getting shingles. This is currently shown to be safe to give people 50 years and older to prevent shingles. Researchers want to test how safe the vaccine is and how it works in people with CLL.

Objective:

  • To learn how a new shingles vaccine works in people who have chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL).

Eligibility:

  • Adults ages 18 years and older with CLL or SLL who are not being treated for CLL or who are getting certain treatments.

Design:

  • Participants will be screened with a chart review or through another protocol.
  • Visit 1
    • At visit 1, participants may have a pregnancy test, blood test, or physical exam.
    • Pregnant participants cannot be in the study.
    • Eligible participants will get the shingles vaccine as an injection.
    • Participants will receive a diary and write down any sumptoms they have for 7 days after the vaccines.
  • Visit 2
    • Visit 2 will be 3 months later. Participants will have blood taken and get another dose of the vaccine.
    • Participants will receive a diary and write down any symptoms they have for 7 days after the vaccines.
  • Visit 3
    • Visit 3 will be 3 months after visit 2. Participants will have blood taken.
    • Participants may be able to get an additional vaccine the same day as the shingles vaccine.

 

Description

This study aims to determine the efficacy of the SHINGRIX varicella zoster virus (VZV) vaccine in chronic lymphocytic leukemia (CLL) patients that are treatment naive or receiving Bruton s-tyrosine kinase inhibitor (BTK-I) therapy.

Key Eligibility Criteria:

  • Diagnosis of CLL
  • Cohort 1: Treatment naive CLL patients
  • Cohort 2: Subjects must be receiving ibrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose
  • Cohort 3: Subjects must be receiving acalabrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose
  • Age greater than or equal to 18 years
  • ECOG performance status of 0-1

Design:

Patients with CLL will enroll on the study for the purpose of determining the SHINGRIX vaccine efficacy in patients who are treatment naive or receiving BTK-I therapy. A series of 2 doses of SHINGRIX will be given at 0- and 3- month schedule by intramuscular injection. Subjects will be followed for 6 months and receive assessment of serologic response 6 months after the first vaccine dose administration.

Study Objectives:

Primary Objective:

  • Determine the serologic response against VZV after completing the SHINGRIX (RZV) 2-dose vaccine series in the following populations:
    • CLL patients that are treatment naive (n=54)
    • CLL patients receiving treatment with ibrutinib (n=27)
    • CLL patients receiving treatment with acalabrutinib (n=27)

Secondary Objective:

  • Determine the safety and tolerability of the SHINGRIX vaccine among CLL patients who are treatment naive or receiving BTK-Is (ibrutinib or acalabrutinib).

 

Details
Condition Chronic Lymphocytic Leukemia
Clinical Study IdentifierTX218184
Last Modified on9 April 2019

Eligibility

Yes No Not Sure

Inclusion Criteria

Diagnosis of CLL
Cohort 1:Treatment na1ve CLL patients
Cohort 2: Subjects must be receiving treatment ibrutinib for at least 6 months prior to administration of the first vaccine dose
Cohort 3: Subjects must be receiving acalabrutinib for at least 6 months prior to administration of the first vaccine dose
No active, symptomatic VZV or herpes zoster infection within 12 months prior to vaccination
No exposure to the live VZV vaccine (ZOSTAVAX) within 12 months prior to vaccination
No prior exposure to the SHINGRIX vaccine
Age greater than or equal to 18 years
ECOG performance status of 0-2
Able to comprehend the investigational nature of the protocol and provide informed consent

Exclusion Criteria

Female patients who are currently in pregnancy
Any uncontrolled active systemic infection
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
Severe allergic reaction to any component of SHINGRIX
Received intravenous immunoglobulin (IVIG) within 3 months prior to vaccination
Concomitant use of immunosuppressive agents (e.g. steroids, radiotherapy, chemotherapy)
Hereditary or acquired immunodeficiency syndrome unrelated to chronic lymphocytic leukemia
Non-English speaking individuals will be excluded from the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note